Skip to content

COMET: Near-patient testing to guide COPD maintenance treatment in primary care

Near-patient testing to guide COPD MaintenancE Treatment in primary care (COMET): observational study to determine variability and accuracy of inflammatory biomarkers in stable state

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ISRCTN
Registry ID
ISRCTN12181464
Enrollment
100
Registered
2017-01-31
Start date
2017-01-01
Completion date
Unknown
Last updated
2020-04-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Specialty: Primary Care, Primary sub-specialty: Respiratory disorders

Interventions

Eligible participants will receive a letter from their GP inviting them to take part in the study, and return a reply form to the study team. They will have four appointments, at which details of thei

Sponsors

University of Oxford
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Participant is willing and able to give informed consent for participation in the study 2. Male or Female, aged 40 years or above 3. Have a diagnosis of COPD meeting spirometric criteria for diagnosis of COPD (FEV1/FVC ratio <0.7) as recorded in their primary care records

Exclusion criteria

Exclusion criteria: 1. Any previous diagnosis of bronchiectasis, cystic fibrosis, interstitial lung disease, lung cancer, alpha-1 anti-trypsin deficiency or other chronic respiratory disease not related to COPD or asthma 2. Co-existent active diagnosis of asthma (reviewed in the last 2 years) 3. Currently prescribed an ICS, or had a prescription for ICS in the last 2 years 4. Regularly takes oral steroids, or has been regularly taking oral steroids in the last 2 years. Regular use of oral steroids will in general be defined as a longer than 2 week course, although discrete short courses with tapering are acceptable for inclusion. 5. Prior inclusion in a clinical trial of an investigational medicinal product for airways disease in the last 90 days or which may involve administration of oral or inhaled steroid treatment

Design outcomes

Primary

MeasureTime frame
Biomarker levels (eosinophils, FeNO, CRP, periostin) are measured at baseline, 2, 4 and 6 months

Secondary

MeasureTime frame
1. Diagnostic accuracy of near-patient eosinophils compared to laboratory eosinophils is assessed using fingerprick blood test at baseline, 2, 4 and 6 months 2. Feasibility of undertaking such measurements in a primary care setting is assessed using surveys created for the purpose of this study at 6 months

Countries

United Kingdom

Contacts

Public ContactHelen Ashdown
comet@phc.ox.ac.uk+44 1865 617868

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026